If all indications were a weekly injection like HI
Post# of 148331
Even given dosage variations with 65 indications and most likely quite a few more than that and if we can bring the price down to $35,000 a year/ $673 per 700mg dose than 20 million+ patients (at any point in time) may be possible worldwide. Which would be 2 billion vials but it won't happen anytime soon.
Of course with lowered price and the cut given to overseas distributors revenue and earnings take a hit. But $700 billion gross with a 20% net is still $140 billion in earnings. $197 a share with 1x P/E. I think that could comfortably give us a four figure share price.